TLDR Anti-androgens might help reduce COVID-19 severity in men.
The document investigated the potential of anti-androgens as treatments for COVID-19, particularly due to their role in modulating androgen-related pathways that might affect disease severity. It highlighted studies suggesting that androgen-deprivation therapies, used for prostate cancer, could reduce severe COVID-19 outcomes. A population-based study with 4,532 participants indicated a potential protective effect against SARS-CoV-2 infection. Additionally, 5-alpha-reductase inhibitors were linked to fewer COVID-19 symptoms in males with androgenetic alopecia. Proxalutamide, an anti-androgen, was noted for significantly accelerating viral clearance and reducing clinical remission time in mild to moderate COVID-19 cases. Despite these promising findings, the document concluded that further research was necessary to confirm the efficacy of anti-androgens in managing COVID-19.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
4 citations
,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
58 citations
,
December 2020 in “Mayo Clinic Proceedings” The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
23 citations
,
September 2021 in “Frontiers in Cellular and Infection Microbiology” Testosterone's effects on COVID-19 are unclear and need more research.
185 citations
,
August 2020 in “Mayo Clinic Proceedings” Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.